TRAVERE THERAPEUTICS, INC. Shareholders' Equity
TRAVERE THERAPEUTICS, INC. (TVTX) had Shareholders' Equity of $24.52 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $24.52M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $98.73M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $114.83M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $73.56M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $24.52M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $98.73M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $114.83M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $73.56M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $32.75M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $32.82M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $59.08M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | -$30.45M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $15.15M 10-Q · filed 2025-10-30 | |
| 2024-03-31 | $74.07M 10-Q · filed 2025-08-06 | |
| 2023-12-31 | $200.81M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $279.77M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $116.48M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $189.14M 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $42.85M 10-K · filed 2026-02-19 | |
| 2022-09-30 | $100.68M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $156.71M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $208.14M 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $302.11M 10-K · filed 2025-02-21 | |
| 2021-09-30 | $307.37M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $332.30M 10-Q · filed 2022-10-27 | |
| 2021-03-31 | $362.69M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $211.21M 10-K · filed 2024-02-20 | |
| 2020-09-30 | $301.41M 10-Q · filed 2021-10-29 | |
| 2020-06-30 | $318.64M 10-Q · filed 2021-10-29 | |
| 2020-03-31 | $225.75M 10-Q · filed 2021-07-29 | |
| 2019-12-31 | $221.20M 10-K · filed 2023-02-23 | |
| 2019-09-30 | $245.96M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $277.09M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $285.71M 10-Q · filed 2020-07-31 | $285.71M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $318.25M 10-K · filed 2022-02-24 | |
| 2018-09-30 | $319.06M 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $287.99M 10-Q · filed 2019-10-30 | |
| 2018-03-31 | $299.48M 10-Q · filed 2019-08-06 | |
| 2017-12-31 | $293.13M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $304.52M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $295.83M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $300.94M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $307.77M 10-K · filed 2020-02-24 | |
| 2016-09-30 | $307.60M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $314.37M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $319.23M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $299.97M 10-K · filed 2019-02-26 | |
| 2015-09-30 | $291.01M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $150.78M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $168.57M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | -$37.25M 10-K · filed 2018-07-06 | -$37.25M 10-K · filed 2015-03-11 |
| 2014-09-30 | -$10.19M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $1.07M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$35.39M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | -$19.67M 10-K · filed 2017-03-01 | -$18.31M 10-K · filed 2014-03-28 |
| 2013-09-30 | -$9.58M 10-Q/A · filed 2015-07-09 | -$5.80M 10-Q · filed 2013-11-13 |
| 2013-06-30 | -$8.46M 10-Q · filed 2013-09-16 | |
| 2013-03-31 | -$3.58M 10-Q/A · filed 2013-09-16 | -$3.22M 10-Q · filed 2013-07-24 |
| 2012-12-31 | -$3.41M 10-K · filed 2016-02-26 | -$3.41M 10-K · filed 2013-06-13 |
| 2012-11-30 | -$64.75K 10-Q · filed 2013-03-06 | |
| 2012-08-31 | -$64.09K 10-Q · filed 2012-10-10 | |
| 2012-05-31 | -$63.59K 10-Q · filed 2012-08-08 | |
| 2012-02-29 | -$63.08K 10-Q · filed 2013-03-06 | |
| 2011-12-31 | -$536.28K 10-Q/A · filed 2015-07-09 | |
| 2011-11-30 | -$61.82K 10-Q · filed 2012-01-11 | |
| 2011-03-10 | $0.00 10-Q · filed 2013-11-13 | |
| 2011-02-28 | -$60.26K 10-Q/A · filed 2012-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |